Access this chapter
Tax calculation will be finalised at checkout
Purchases are for personal use only
Preview
Unable to display preview. Download preview PDF.
References and Further Reading
Adachi M, Wallace BJ, Schneck L, Volk BW. Fine structure of spongy degeneration of the central nervous system (van Bogaert and Betrand type). J Neuropathol Exp Neurol 1966; 25: 598–616
Adachi M, Volk BW. Protracted form of spongy degeneration of the central nervous system. Neurology 1968; 18: 1084–1092
Adachi M, Torii J, Schneck L, Volk BW. Electron microscopic and enzyme histochemical studies of the cerebellum in spongy degeneration. Acta Neuropathol (Berl) 1972; 20: 22–31
Adachi M, Schneck L, Cara J, Volk BW. Spongy degeneration of the central nervous system (Van Bogaert and Bertrand type; Canavan’s disease). Hum Pathol 1973; 4: 331–347
Austin SJ, Connelly A, Gadian DG, Benton JS, Brett EM. Localized 1H NMR spectroscopy in Canavan’s disease: a report of two cases. Magn Reson Med 1991; 19: 439–445
Banker BQ, Robertson JT, Victor M. Spongy degeneration of the central nervous system in infancy. Neurology 1964; 14: 981–1001
Barker PB, Bryan RN, Kumar AJ, Naidu S. Proton NMR spectroscopy of Canavan’s disease. Neuropediatrics 1992; 23: 263–267
Baslow MH. Molecular water pumps and the aetiology of Canavan’s disease: a case of sorcerer’s apprentice. J Inherit Metab Dis 1999; 22: 99–101
Baslow MH. Canavan’s spongiform leukodystrophy. A clinical anatomy of a genetic metabolic CNS disease. J Mol Neurosci 2000; 15: 61–69
Baslow MH. Evidence supporting a role for N-acetyl-L-aspartate as a molecular water pump in myelinated neurons in the central nervous system. An analytical review. Neurochem Int 2002; 40: 295–300
Baslow MH. Brain N-acetylaspartate as a molecular water pump and its role in the etiology of Canavan disease. J Mol Neurosci 2003; 21: 185–189
Baslow MH, Resnik TR. Canavan Disease. Analysis of the nature of the metabolic lesions responsible for development of the observed clinical symptoms. J Mol Neurosci 1997; 9: 109–125
Baslow MH, Suckow RF, Sapirstein V, Hungund BL. Expression of aspartoacylase activity in cultured rat macroglial cells is limited to oligodendrocytes. J Mol Neurosci 1999; 13: 47–53
Bennett MJ, Gibson KM, Sherwood WG, Divry P, Rolland MO, Elpeleg ON, Rinaldo P, Jakobs C. Reliable prenatal diagnosis of Canavan disease (aspartoacylase deficiency): comparison of enzymatic and metabolite analysis. J Inherit Metab Dis 1993; 16: 831–836
Besley GTN, Elpeleg ON, Shaag A, Manning NJ, Jakobs C, Walter JH. Prenatal diagnosis of Canavan disease. Problems and dilemmas. J Inherit Metab Dis 1999; 22: 263–366
Brismar J, Brismar G, Gascon G, Ozand P. Canavan disease: CT and MR imaging of the brain. AJNR Am J Neuroradiol 1990; 11: 805–810
Brown LW, Rorke LB, Deray MJ, Smith SB, Altman N. Psychomotor retardation and macrocephaly in an infant. Pediatr Neurosci 1985–1986; 12: 266–271
Burlina AP, Ferrari V, Divry P, Gradowska W, Jakobs C, Bennett MJ, Sewell AC, Dionisi-Vici C, Burlina AB. N-Acetylaspartylglutamate in Canavan disease: an adverse effector? Eur J Pediatr 1999; 158: 406–409
De Coo IFM, Gabreëls FJM, Renier WO, de Pont JJHHM, Hälst UJGM, Veerkamp JH, Trijbels JMF, Jaspar HHJ, Renkawek. Canavan disease: neuromorphological and biochemical analysis of a brain biopsy specimen. Clin Neuropathol 1991; 10: 73–78
Echenne B, Divry P, Vianey-Liaud C. Spongy degeneration of the neuraxis (Canavan-Van Bogaert disease) and N-acetylaspartic aciduria. Neuropediatrics 1989; 20: 70–81
Engelbrecht V, Scherer A, Rassek M, Witsack HJ, Mödder U. Diffusion-weighted MR imaging in the brain in children: findings in the normal brain and in the brain with white matter diseases. Radiology 2002; 222: 410–418
Gascon GG, Ozand PT, Mahdi A, Jamil A, Haider A, Brismar J, Al-Nasser M. Infantile CNS spongy degeneration-14 cases: clinical update. Neurology 1990; 40: 1876–1882
Gordon N. Canavan disease: a review of recent developments. Eur J Paediatr Neurol 2000; 5: 65–69
Grod W, Krägeloh-Mann I, Petersen D, Trefz FK, Harzer K. In vivo assessment of N-acetylaspartate in brain in spongy degeneration (Canavan’s disease) by proton spectroscopy. Lancet 1990; 336: 437–438
Hagenfeldt L, Bollgren I, Venizelos N. N-Acetylaspartic aciduria due to aspartoacylase deficiency — a new aetiology of childhood leucodystrophy. J Inherit Metab Dis 1987; 10: 135–141
Hamaguchi H, Nihei K, Nakamoto N, Ezoe T, Naito H, Hara M, Yokota K, Inoue Y, Matsumoto I. A case of Canavan disease: the first biochemically proven case in a Japanese girl. Brain Dev 1993; 15: 367–371
Janson C, McPhee S, Bilaniuk L, Haselgrove J, Testaiuti M, Freese A, Wang D-J, Shera D, Hurh P, Rupin J, Saslow E, Goldfarb O, Goldberg M, Larijani G, Sharrar W, Liouterman L, Camp A, Kolodny E, Samulski J, Leone P. Gene therapy of Canavan disease: AAV-2 vector for neurosurgical delivery of aspartoacylase gene (ASPA) to the human brain. Hum Gene Ther 2002; 13: 1391–1412
Kamoshita S, Rapin I, Suzuki K, Suzuki K. Spongy degeneration of the brain. Neurology 1968; 18: 975–985
Kaul R, Gao GP, Balamurugan K, Matalon R. Cloning of the human aspartoacylase cDNA and a predominant missense mutation in Canavan disease. Nat Genet 1993; 5: 118–123
Kendall BE. Disorders of lysosomes, peroxisomes, and mitochondria. AJNR Am J Neuroradiol 1992; 13: 621–653.
Kirmani BF, Jocobowitz DM, Kallarakal AT, Namboodiri MAA. Aspartoacylase is restricted primarily to myelin synthesizing cells in the CNS: therapeutic implications for Canavan disease. Mol Brain Res 2002; 107: 176–183
Kvittingen EA, Guldal G, Borsting S, Skalpe IO, Stokke O, Jellum E. N-acetylaspartic aciduria in a child with a progressive cerebral atrophy. Clin Chim Acta 1986; 158: 217–227
Leone P, Janson CG, Bilianuk L, Wang Z, Sorgi F, Huang L, Matalon R, Kaul R, Zeng Z, Freese A, McPhee SW, Mee E, During MJ. Aspartoacylase gene transfer to the mammalian central nervous system with therapeutic implications for Canavan disease. Ann Neurol 2000; 48: 27–38
Mahloudji M, Daneshbod K, Karjoo M. Familial spongy degeneration of the brain. Arch Neurol 1970; 22: 294–298
Marks HG, Caro PA, Wang Z, Detre JA, Bogdan AR, Gusnard DA, Zimmerman RA. Use of computed tomography, magnetic resonance imaging, and localized 1H magnetic resonance spectroscopy in Canavan’s disease: a case report. Ann Neurol 1991; 30: 106–110
Matalon R, Michals-Matalon K. Prenatal diagnosis of Canavan disease. Prenat Diagn 1999; 19: 669–670
Matalon R, Michals-Matalon K. Spongy degeneration of the brain, Canavan disease: biochemical and molecular findings. Pediatr Pathol Mol Med 2000; 18: 471–481
Matalon R, Michals K, Sebesta D, Deanching M, Gashkoff P, Casanova J. Aspartoacylase deficiency and N-acetylaspartic aciduria in patients with Canavan disease. Am J Med Genet 1988; 29: 463–471
Matalon R, Kaul R, Casanova J, Michals K, Johnson A, Rapin I, Gashkoff P, Deanching M. Aspartoacylase deficiency: the enzyme defect in Canavan disease. J Inherit Metab Dis 1989; 12: 329–331
Matalon R, Kaul R, Michals K. Canavan disease: biochemical and molecular studies. J Inherit Metab Dis 1993; 16: 744–752
Matalon R, Michals K, Kaul R. Canavan disease: from spongy degeneration to molecular analysis. J Pediatr 1995; 127: 511–517
Matalon R, Kaul R, Gao GP, Michals K, Gray RGF, Bennett-Briton S, Norman A, Smith M, Jakobs C. Prenatal diagnosis for canavan disease: the use of DNA markers. J Inherit Metab Dis 1995; 18: 215–217
Matalon R, Rady PL, Platt KA, Skinner HB, Quast MJ, Campbell GA, Metalon K, Ceci JD, Tyring SK, Nehls M, Surendran S, Wei J, Ezell EL, Szucs S. Knock-out mouse for Canavan disease: a model for gene transfer tot the central nervous system. J Gene Med 2000; 2: 165–175
Meyding-Lamadé U, Sartor K. Magnetresonanztomographie bei neurodegenerativen Erkrankungen im Kindesalter. Klin Neuroradiol 1993; 3: 52–61
Toft PB, Geiß-Holtorff R, Roland MO, Pryd SO, Mueller-Forell W, Christensen E, Lehnert W, Lou HC, Ott D, Hennig J, Henriksen O. Magnetic resonance imaging in juvenile Canavan disease. Eur J Pediatr 1993; 152: 750–753
Topçu M, Erdem G, Saatçi I, Aktan G, Şimşek A A, Renda Y, Schutgens RBH, Wanders RJA, Jacobs C. Clinical and magnetic resonance imaging features of L-2-hydroxyglutaric academia: report of three cases in comparison with Canavan disease. J Child Neurol 1996; 11: 373–377
Traeger E, Rapin I. The clinical course of Canavan disease. Pediatr Neurol 1998; 18: 207–212
Van Bogaert L, Bertrand I. Les leucodystrophies progressives familiales. Rev Neurol 1933; 2: 249–286
Wittsack HJ, Kugel H, Roth B, Heindel W. Quantitative measurements with localized 1H MR spectroscopy in children with Canava’s disease. J Magn Reson Imaging 1996; 6: 889–893
Zafeiriou D, Kleijer WJ, Maropoulos G, Anastasiou AL, Augoustidou-Savvopoulou P, Papadopoulou F, Kontopuolos EE, Fagan E, Payne S. Protracted course of N-acetylaspartic aciduria in two non-Jewish siblings: identical clinical and magnetic resonance imaging findings. Brain Dev 1999; 21: 205–208
Zelnik N, Amir N, Luder AS, Hemli JA, Elpeleg ON, Fatal A, Gross-Tsur V, Harel S. Protracted clinical course for patients with Canavan disease. Dev Med Child Neurol 1993; 35: 346–358
Rights and permissions
Copyright information
© 2005 Springer-Verlag Berlin Heidelberg
About this chapter
Cite this chapter
(2005). Canavan Disease. In: Magnetic Resonance of Myelination and Myelin Disorders. Springer, Berlin, Heidelberg. https://doi.org/10.1007/3-540-27660-2_42
Download citation
DOI: https://doi.org/10.1007/3-540-27660-2_42
Publisher Name: Springer, Berlin, Heidelberg
Print ISBN: 978-3-540-22286-6
Online ISBN: 978-3-540-27660-9
eBook Packages: MedicineMedicine (R0)